Authors
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Darolutamide/ADT Yields OS Benefit in mHSPC Across All Disease VolumesFindings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.
Latest:
Ferdinandos Skoulidis, MD, PhD, MRCP, Discusses Exciting Research in the Lung Cancer Field From ASCO 2021Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.
Latest:
Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?KEY POINTS • Synovial sarcomas are often mistreated with unplanned tumor resection. • Attention from specialists early in the course of SS can minimize the risk of recurrence, metastases, and the necessity for resurgery, all of which are increased with unplanned tumor resection. • Chemotherapy alone does not provide sufficient local control of the tumor. • Resurgery, in conjunction with radiotherapy and chemotherapy, is the best choice of management for this patient.
Latest:
Exploring Next-Line Options in HER2- MSS Gastric CancerExperts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.
Latest:
Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With CancerImmunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
Latest:
Input From a Multidisciplinary Team of Medical Providers is ‘Necessary’ to Manage Contralateral Breast Cancer, Says ExpertIt takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
Latest:
Non-BCMA Targeting Bispecifics in MM and Future Directions in CareBefore closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.
Latest:
PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment LandscapePanelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.
Latest:
Bispecifics in R/R MM: Key TakeawaysPanelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.
Latest:
Cardiovascular Considerations in Breast Cancer Treatment and SurvivorshipUp-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Latest:
Practice Pearls for Optimizing the Management of Advanced RCCExperts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.
Latest:
Guidelines for Opioid Use in Cancer Management are Needed, Expert SaysAlthough opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Latest:
Taking the Next Steps to Advance Supportive Care in LeukemiaExperts at the 2025 National ICE-T Conference discussed the need for improved management of toxicities in patients with leukemia.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Artificial Intelligence May Expedite Prognoses in Cancer CareIn considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Latest:
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From EndometriosisLearn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple MyelomaA Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
Latest:
Key Takeaways and Future Directions in Later Relapsed/Refractory MMPanelists discuss how talquetamab’s unique targeting mechanism offers significant advantages for patients with prior T-cell therapy exposure, whereas future research should focus on combination strategies and understanding primary resistance mechanisms.
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
